ScyFIX seeks $4M for eye device; Smiths Group reports earnings, no news on possible breakup;

> ScyFIX is seeking to raise $4 million as the Chanhassen, MN-based company continues to seek FDA approval for a device that uses slight electric shocks to treat degenerative eye disease. Story

> Smiths Group reported better-than-expected first-half earnings and signaled it was confident it would meet its expectations for the year despite the uncertain economic environment. It offered no information that suggested a breakup of the industrial conglomerate. News

> OraSure Technologies has submitted to the FDA an application for a waiver under the Clinical Laboratory Improvement Amendments of 1988 for its OraQuick HCV Rapid Antibody Test for use with venous whole blood and fingerstick whole blood specimens. OraSure release

> Galway medical device company AeroSurgical has secured investment of €1.6 million from the Western Development Commission, Enterprise Ireland, existing shareholders and new private investors. Article

> Engineers have designed a lens that enables microscopic objects to be seen from nine different angles at once to create a 3D image. Allen Yi, associate professor of integrated systems engineering at Ohio State University, called the lens a proof of concept for manufacturers of microelectronics and medical devices, the Journal of the Optical Society of America A reports. Item

And Finally... A Las Vegas Valley urologist whose medical license has been suspended for reusing single-use needle guides blames an unnamed equipment vendor for suggesting he could do so, according to a paid advertisement in today's Review-Journal. Report

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.